Mawer Investment Management Ltd. Has $37.78 Million Position in West Pharmaceutical Services, Inc. (NYSE:WST)

Mawer Investment Management Ltd. reduced its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 0.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 133,335 shares of the medical instruments supplier’s stock after selling 289 shares during the period. Mawer Investment Management Ltd. owned about 0.18% of West Pharmaceutical Services worth $37,775,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Harvest Investment Services LLC raised its holdings in West Pharmaceutical Services by 2.9% during the third quarter. Harvest Investment Services LLC now owns 1,346 shares of the medical instruments supplier’s stock worth $370,000 after acquiring an additional 38 shares in the last quarter. Vident Investment Advisory LLC grew its position in West Pharmaceutical Services by 1.5% during the fourth quarter. Vident Investment Advisory LLC now owns 2,769 shares of the medical instruments supplier’s stock worth $784,000 after buying an additional 40 shares in the last quarter. Dorsey Wright & Associates grew its position in West Pharmaceutical Services by 0.4% during the fourth quarter. Dorsey Wright & Associates now owns 10,953 shares of the medical instruments supplier’s stock worth $3,103,000 after buying an additional 43 shares in the last quarter. Parallel Advisors LLC boosted its holdings in shares of West Pharmaceutical Services by 39.8% in the 4th quarter. Parallel Advisors LLC now owns 172 shares of the medical instruments supplier’s stock valued at $49,000 after purchasing an additional 49 shares in the last quarter. Finally, IFP Advisors Inc boosted its holdings in shares of West Pharmaceutical Services by 96.2% during the 3rd quarter. IFP Advisors Inc now owns 104 shares of the medical instruments supplier’s stock valued at $29,000 after acquiring an additional 51 shares in the last quarter. 92.55% of the stock is owned by institutional investors.

NYSE:WST traded down $0.15 during trading hours on Tuesday, hitting $272.50. 4,731 shares of the company were exchanged, compared to its average volume of 532,532. The stock has a market capitalization of $20.15 billion, a price-to-earnings ratio of 71.01, a price-to-earnings-growth ratio of 3.86 and a beta of 1.13. The company has a current ratio of 2.96, a quick ratio of 2.23 and a debt-to-equity ratio of 0.16. West Pharmaceutical Services, Inc. has a one year low of $124.53 and a one year high of $312.12. The company has a fifty day simple moving average of $296.27 and a 200 day simple moving average of $282.51.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, February 18th. The medical instruments supplier reported $1.34 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.13 by $0.21. West Pharmaceutical Services had a return on equity of 19.01% and a net margin of 14.69%. Equities research analysts predict that West Pharmaceutical Services, Inc. will post 4.27 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, February 3rd. Stockholders of record on Wednesday, January 20th were given a $0.17 dividend. This represents a $0.68 annualized dividend and a dividend yield of 0.25%. The ex-dividend date of this dividend was Tuesday, January 19th. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 20.99%.

Separately, KeyCorp started coverage on West Pharmaceutical Services in a research report on Monday, November 9th. They set an “overweight” rating and a $350.00 target price for the company.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, Ireland, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

Featured Story: Risk Tolerance

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.